First quarter 2023 results

First quarter 2023 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.

Featuring

Paul Hudson

Paul Hudson

Chief Executive Officer

 Jean-Baptiste de Chatillon

Jean-Baptiste de Chatillon

Chief Financial Officer

 Bill Sibold

Bill Sibold

Specialty Care

Olivier Charmeil

Olivier Charmeil

General Medicines

Dietmar Berger

Dietmar Berger

Global Head of R&D ad interim

Thomas Triomphe

Thomas Triomphe

Vaccines

Julie van Ongevalle

Julie van Ongevalle

Consumer Healthcare

Roy Papatheodorou

Roy Papatheodorou

General Counsel

Highlights

We have started 2023 with strong results, delivering double-digit sales growth across our Specialty Care, Vaccines and Consumer Healthcare businesses. With two best in class launches this year and the acceleration of our early-mid stage pipeline, we are well underway.
Paul Hudson,

Paul Hudson,

Chief Executive Officer

Downloads

Press release

Presentation

Q1 2023 Income statements

Q1 2023 net sales by GBU, franchise, geographic region and product

R&D appendix

Download infographic

Q1 2023 Memorandum for modelling purposes

Contact

Investor Relations

investor.relations@sanofi.com

More contact information